StockData
BioNexus Gene Lab Corp logo

BioNexus Gene Lab Corp (BGLC) stock

BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3090% below fair value
$0.77−0.05 (-6.56%)

Close on Nov 17, 2026Market cap $2.25MP/E –Yield –

BioNexus Gene Lab operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BioNexus Gene Lab's operating income for the twelve months ending Jun 30, 2026 was -$2.56M. For fiscal 2025 it was -$2.97M. The highest annual figure on record is $1.27M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$2.97M–
FY2024Dec 31, 2024-$1.57M–
FY2023Dec 31, 2023-$2.59M–
FY2022Dec 31, 2022-$291.18K-127.6%
FY2021Dec 31, 2021$1.06M-17.1%
FY2020Dec 31, 2020$1.27M–
FY2019Dec 31, 2019-$275.71K-560.3%
FY2018Dec 31, 2018$59.90K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$282.40K–
Q1 FY2026Mar 31, 2026-$540.49K–
Q4 FY2025Dec 31, 2025-$1.03M–
Q3 FY2025Sep 30, 2025-$702.51K–
Q2 FY2025Jun 30, 2025-$611.29K-335.9%
Q1 FY2025Mar 31, 2025-$618.42K–
Q4 FY2024Dec 31, 2024-$416.22K-261.5%
Q3 FY2024Sep 30, 2024-$1.34M–
Q2 FY2024Jun 30, 2024$259.17K–
Q1 FY2024Mar 31, 2024-$79.03K–
Q4 FY2023Dec 31, 2023$257.75K–
Q3 FY2023Sep 30, 2023-$2.53M–
Q2 FY2023Jun 30, 2023-$272.20K–
Q1 FY2023Mar 31, 2023-$50.63K-245.9%
Q4 FY2022Dec 31, 2022-$122.69K-161.0%
Q3 FY2022Sep 30, 2022-$65.22K-117.5%
Q2 FY2022Jun 30, 2022-$137.96K-198.6%
Q1 FY2022Mar 31, 2022$34.69K-89.9%
Q4 FY2021Dec 31, 2021$201.06K–
Q3 FY2021Sep 30, 2021$372.64K+57.0%
Q2 FY2021Jun 30, 2021$139.99K–
Q1 FY2021Mar 31, 2021$342.10K-68.1%
Q4 FY2020Dec 31, 2020-$3.04K–
Q3 FY2020Sep 30, 2020$237.31K–
Q2 FY2020Jun 30, 2020-$33.97K–
Q1 FY2020Mar 31, 2020$1.07M–
Q4 FY2019Dec 31, 2019-$96.15K–
Q3 FY2019Sep 30, 2019-$50.14K–
Q2 FY2019Jun 30, 2019-$69.22K–
Q1 FY2019Mar 31, 2019-$60.20K–
Q4 FY2018Dec 31, 2018-$63.35K–
Q3 FY2018Sep 30, 2018-$55.14K–
Q2 FY2018Jun 30, 2018-$39.47K–

More BioNexus Gene Lab figures

See a number that looks wrong?